EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of Azacitidine in Patients With RUNX1::RUNX1T1 Measurable Residual Disease-Positive Acute Myeloid Leukemia After Consolidation Therapy Who Did Not Undergo Allogeneic Hematopoietic Stem-Cell Transplantation

Huazhou Shi, Dapeng Peng, Nannan Qi, Yan Wang, Zhiyun Niu, Jingyu Zhang

Clinical Lymphoma Myeloma and Leukemia · 2026-11 · 26 (11) · e1355-e1365

DOI: 10.1016/j.clml.2026.09.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-11. Verfasst von Huazhou Shi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China; Department of Hematology, Henan Cancer Hospita…. Hauptthemen laut MEDLINE: Azacitidine, Leukemia, Myeloid, Acute, Core Binding Factor Alpha 2 Subunit, Consolidation Chemotherapy. Die Arbeit nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: We assessed the efficacy and safety of azacitidine (AZA) in patients with RUNX1::RUNX1T1 measurable residual disease (MRD)-positive acute myeloid leukemia (AML) after consolidation who did not undergo allogeneic hematopoietic stem-cell transplantation (allo-HSCT), and descriptively compared outcomes with a contemporaneous allo-HSCT cohort. METHODS: We retrospectively analyzed 60 patients with persistent/recurrent RUNX1::RUNX1T1 MRD positivity after consolidation (46 received AZA, 14 underwent allo-HSCT). Progression-free survival (PFS; primary endpoint), cumulative incidence of relapse (CIR), overall survival (OS) and complications were assessed. RESULTS: After median follow-up 36 months, 3-year PFS and OS were 65.0% and 71.1%. The 3-year CIR was higher with AZA than allo-HSCT (37.0% vs. 7.1%; Gray P = .046), whereas no statistically significant differences in PFS (63.0% vs. 71.4%; log-rank P = .68) or OS (70.8% vs. 71.4%; log-rank P = .93) were observed; this comparison was exploratory and underpowered. KIT mutation, not treatment group, independently predicted shorter PFS and OS. AZA patients had fewer complications and no treatment-related deaths. CONCLUSION: In this small, retrospective, non-randomized study, AZA was associated with a higher relapse incidence than allo-HSCT; no significant differences in PFS or OS were observed, although the study was underpowered to establish equivalence. AZA showed favorable toxicity and may represent a feasible option for MRD-positive patients who do not undergo transplant. Larger prospective studies are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzacitidineLeukemia, Myeloid, AcuteCore Binding Factor Alpha 2 SubunitConsolidation ChemotherapyRUNX1 Translocation Partner 1 ProteinAntimetabolites, AntineoplasticHumansFemaleMaleNeoplasm, ResidualRetrospective StudiesMiddle AgedAdultHematopoietic Stem Cell TransplantationTransplantation, HomologousYoung AdultAged

Stichwörter der Autor:innen

Acute myeloid leukaemiaAllogeneic haematopoietic stem-cell transplantationAzacitidineMeasurable residual diseaseRUNX1::RUNX1T1

Substanzen

AzacitidineCore Binding Factor Alpha 2 SubunitRUNX1 Translocation Partner 1 ProteinRUNX1 protein, humanAntimetabolites, AntineoplasticRUNX1T1 protein, human

Autor:innen und Institutionen

  • Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China; Department of Hematology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou,…
  • Department of Haematopoietic Stem Cell Transplantation, Beijing Lu Daopei Hospital, Beijing, China.
  • Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
  • Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. Electronic address: 26900170@hebmu.edu.cn.

Zitieren

APA

Shi, H., Peng, D., Qi, N., Wang, Y., Niu, Z., & Zhang, J. (2026). Efficacy and Safety of Azacitidine in Patients With RUNX1::RUNX1T1 Measurable Residual Disease-Positive Acute Myeloid Leukemia After Consolidation Therapy Who Did Not Undergo Allogeneic Hematopoietic Stem-Cell Transplantation. Clinical Lymphoma Myeloma and Leukemia, 26(11), e1355-e1365. https://doi.org/10.1016/j.clml.2026.09.006

Vancouver

Shi H, Peng D, Qi N, Wang Y, Niu Z, Zhang J. Efficacy and Safety of Azacitidine in Patients With RUNX1::RUNX1T1 Measurable Residual Disease-Positive Acute Myeloid Leukemia After Consolidation Therapy Who Did Not Undergo Allogeneic Hematopoietic Stem-Cell Transplantation. Clinical Lymphoma Myeloma and Leukemia. 2026;26(11):e1355-e1365. doi:10.1016/j.clml.2026.09.006

BibTeX
@article{Shi2026,
  author = {Shi, Huazhou and Peng, Dapeng and Qi, Nannan and Wang, Yan and Niu, Zhiyun and Zhang, Jingyu},
  title = {Efficacy and Safety of Azacitidine in Patients With RUNX1::RUNX1T1 Measurable Residual Disease-Positive Acute Myeloid Leukemia After Consolidation Therapy Who Did Not Undergo Allogeneic Hematopoietic Stem-Cell Transplantation},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  volume = {26},
  number = {11},
  pages = {e1355--e1365},
  doi = {10.1016/j.clml.2026.09.006}
}
Kostenlos starten →